Saturday 17 October 2026
Export VIVS’s income statement to Excel — free account
VivoSim Labs, Inc.
VIVS Healthcare Biotechnology
VivoSim Labs, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $131,000.00, down 9.03% from fiscal 2025. In the quarter to June 2026, revenue fell 51.4%, EPS grew 78.1% and free cash flow grew 17.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.16
0.01
−5.88%
Follow VIVS
VivoSim Labs, Inc. (VIVS) P/E ratio
VivoSim Labs, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 5.5× (October 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 1.0× | (79.33%) |
| Sep 2025 | 4.7× | — |
| 33 more quarters | Free account |
Against its own ten years
Low 0.0×
High 5.5×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SLXN Silexion Therapeutics Corp compare | n/m |
| VIVS VivoSim Labs, Inc. | n/m |
| BCAB BioAtla, Inc. compare | n/m |
| MBIO Mustang Bio, Inc. compare | n/m |
| HCWB HCW Biologics Inc. compare | n/m |
| AFMDQ Affimed N.V. compare | n/m |
| ARAV ARAVIVE, INC compare | n/m |
| ONCO Onconetix, Inc. compare | 0.0× |
| DCOY Decoy Therapeutics Inc compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)